Screening the interactions between HIV-1 neutralizing antibodies and model lipid surfaces

Journal of Immunological Methods

Volumn 376, Issue 1-2, 2012, Pages 13-19

  Hardy, Gregory J ^a   Lam, Yee ^a   Stewart, Shelley M ^b   Anasti, Kara ^b   Alam, S Munir ^b   Zauscher, Stefan ^a  

^a Duke University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV 1; Neutralizing antibody; Surface plasmon resonance; Thiol model surface

Indexed keywords

1 OCTADECANETHIOL; 11 AMINO 1 UNDECANETHIOL; 11 MERCAPTO 1 UNDECANOL; 11 MERCAPTOUNDECANOIC ACID; LIPID; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY 2F5; NEUTRALIZING ANTIBODY 4E10; SELF ASSEMBLED MONOLAYER; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; LIPID BILAYER; LIPID MEMBRANE; LIPID VESICLE; NONHUMAN; PRIORITY JOURNAL; SPECTROSCOPY; SURFACE PLASMON RESONANCE; VIRUS CELL INTERACTION;

ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; LIPIDS; SURFACE PLASMON RESONANCE; SURFACE PROPERTIES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84856522842     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.10.005     Document Type: Article

References (19)

1. Alam S.M., McAdams M., Boren D., Rak M., Scearce R.M., Gao F., Camacho Z.T., Gewirth D., Kelsoe G., Chen P., Haynes B.F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 2007, 178:4424.
2. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K.M., Tartaglia J., Caudrelier P., El Habib R., Klein M., Lazzarin A., Stablein D.M., Deers M., Corey L., Greenberg M.L., Schwartz D.H., Montefiori D.C. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2000, 16:2019.
3. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233.
4. Conley A.J., Kessler J.A., Boots L.J., Tung J.S., Arnold B.A., Keller P.M., Shaw A.R., Emini E.A. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3348.
5. Cooper M.A. Advances in membrane receptor screening and analysis. J. Mol. Recognit. 2004, 17:286.
6. Dubois L.H., Nuzzo R.G. Synthesis, structure, and properties of model organic-surfaces. Annu. Rev. Phys. Chem. 1992, 43:437.
7. Giles I., Lambrianides N., Latchman D., Chen P., Chukwuocha R., Isenberg D., Rahman A. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Res. Ther. 2005, 7:R47.
8. Hauser H., Pasher I., Pearson R.H., Sundell S. Preferred conformation and molecular packing of phosphatidylethanolamine and phosphatidylcholine. Biochim Biophys Acta 1981, 650:21.
9. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906.
10. Im H., Wittenberg N.J., Lesuffleur A., Lindquist N.C., Oh S.H. Membrane protein biosensing with plasmonic nanopore arrays and pore-spanning lipid membranes. Chem. Sci. 2010, 1:688.
11. Liao H.X., Sutherland L.L., Xia S.M., Brock M.E., Scearce R.M., Vanleeuwen S., Alam S.M., McAdams M., Weaver E.A., Camacho Z.T., Ma B.J., Li Y.Y., Decker J.M., Nabel G.J., Montefiori D.C., Hahn B.H., Korber B.T., Gao F., Haynes B.F. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and CHIV-1 primary viruses. Virology 2006, 353:268.
12. MacDonald R.C., MacDonald R.I., Menco B.P., Takeshita K., Subbarao N.K., Hu L.R. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim. Biophys. Acta 1991, 1061:297.
13. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 2004, 78:10724.
14. Sanchez-Martinez S., Lorizate M., Hermann K., Kunert R., Basanez G., Nieva J.L. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 2006, 580:2395.
15. Scearce R.M., Eisenbarth G.S. Production of monoclonal antibodies reacting with the cytoplasm and surface of differentiated cells. Methods Enzymol. 1983, 103:459.
16. Sun Z.Y., Oh K.J., Kim M., Yu J., Brusic V., Song L., Qiao Z., Wang J.H., Wagner G., Reinherz E.L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28:52.
17. Wiltschi B., Knoll W., Sinner E.K. Binding assays with artificial tethered membranes using surface plasmon resonance. Methods 2006, 39:134.
18. Zhu M., Olee T., Le D.T., Roubey R.A., Hahn B.H., Woods V.L., Chen P.P. Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br. J. Haematol. 1999, 105:102.
19. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892.